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CONSPECTUS: The primary function of the cell membrane is to protect cells from their 
surroundings. This entails a strict regulation on controlling the exchange of matter between the 
cell and its environment. A key factor when considering potential biological applications of a 
particular chemical structure has to do with its ability to internalize into cells. Molecules that can 
readily cross cell membranes are frequently needed in biological research and medicine, since most 
therapeutic entities are designed to modulate intracellular components. However, the design of 
molecules that do not penetrate cells is also relevant toward, e.g. extracellular contrast agents, 
which are most widely used in clinical diagnosis.  
Small molecules have occupied the forefront of biomedical research until recently, but the past 
few decades have seen an increasing use of larger chemical structures, such as proteins or 
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nanoparticles, leading to unprecedented and often unexpectedly novel research. Great 
achievements have been made toward understanding the rules that govern cellular uptake, which 
show that cell internalization of molecules is largely affected by their size. For example, 
macromolecules such as proteins and nucleic acids are usually unable to internalize cells. 
Intriguingly, in the case of nanoparticles, larger sizes seem to facilitate internalization via 
endocytic pathways, through which the particles remain trapped in lysosomes and endosomes. 
In this Account, we aimed at presenting our personal view of how different chemical structures 
behave in terms of cell internalization due to their size, ranging from small drugs to large 
nanoparticles. We first introduce the properties of cell membranes and the main mechanisms 
involved in cellular uptake. We then discuss the cellular internalization of molecules, 
distinguishing between those with molecular weights below 1 KDa, and biological 
macromolecules such as proteins and nucleic acids. In the last section, we review the biological 
behavior of nanoparticles, with a special emphasis on plasmonic nanoparticles, which feature a 
high potential in the biomedical field. For each group of chemical structures, we discuss the 
parameters affecting their cellular internalization, but also strategies that can be applied to achieve 
the desired intracellular delivery. Particular attention is paid to approaches that allow conditional 
regulation of the cell internalization process using external triggers, such as activatable cell 
penetrating peptides, due to the impact that these systems may have in drug delivery and sensing 
applications.  The review ends with a “Conclusions and Outlook” section, where general lessons 
and future directions toward further advancements are briefly presented. 
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INTRODUCTION 
Cellular uptake is one of the most important processes regulating the biological activity of 
molecules, and it is determined by the interactions between the molecule and the plasma 
membrane. The plasma membrane is a thin layer (4-10 nm) that forms the outer boundary of cells. 
The two main components of this barrier are lipids and proteins; each of them being associated to 
one of the primary roles of the membrane. Lipids have a morphology task, they form a negatively 
charged bilayer that constitutes the boundary between the cell and its external microenvironment. 
On the other hand, proteins have a functional task, they regulate the exchange of substances 
between internal and external media, and provide cellular signaling.1  
It is vital for cells to tightly regulate the transport of substances through the cell membrane, as 
exemplified by the fact that around 10% of all human genes are transport related.2 Cells use a wide 
range of transport mechanisms that can be grouped into three classes: simple diffusion, facilitated 
diffusion, and active transport. Simple diffusion is a passive process by which molecules move 
across the membrane, driven by a concentration or an electric potential gradient, with no need for 
an intermediary such as a membrane protein.3 This mechanism applies to small and hydrophobic 
molecules, which can cross directly through the hydrophobic region of the phospholipid bilayer. 
Conversely, although facilitated diffusion is also a passive movement, it occurs with the aid of a 
membrane protein. Finally, active transport requires energy from the cell. Cells use this transport 
for two reasons: i) to move substances against a concentration or an electrochemical gradient, or 
ii) to take in larger molecules and particles. When molecules are too large to cross the plasma 
membrane or to move through a transport protein, cells capture these substances from their outside 
by engulfing them with the cell membrane itself. The cargos are then separated from the cytoplasm 
by a lipid membrane, in a process called endocytosis (Figure 1).4  
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Endocytosis can be broadly subdivided into phagocytosis and pinocytosis. Phagocytosis is the 
process by which cells such as macrophages or dendritic cells, engulf particulate matter larger than 
0.5 μm and digest it.5 On the other hand, pinocytosis is involved in the internalization of fluids and 
molecules by small vesicles. Pinocytosis can be further subdivided into various categories, 
depending on the molecular mechanism: 
Macropinocytosis: The surrounding fluid is internalized into large vacuoles by actin-dependent 
membrane protrusion, and results in large intracellular vacuoles (>0.2 μM), known as 
macropinosomes.6 
Clathrin-dependent endocytosis: A vesicular transport event that cells employ to carry out the 
endocytosis of activated cell surface receptors.7 This occurs by the inward budding of plasma 
membrane vesicles, containing proteins with receptor sites that are specific to the molecules being 
internalized.  
Caveolin-dependent endocytosis: An endocytic process involving bulb-shaped, 50-60 nm plasma 
membrane invaginations called caveolae,8 whose formation is driven by integral membrane proteins 
called caveolins.  
Clathrin- and caveolin-independent endocytosis: This is a group of several endocytic pathways 
related to the presence of highly ordered lipid microdomains (40-50 nm in diameter) in the cell 
membrane, called ‘lipid rafts’.9 
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Figure 1. Schematic representation of the endocytic pathways used by cells to internalize molecules. 
Reproduced with permission from ref. 9. Copyright 2007 Springer Nature. 
 
CELLULAR UPTAKE OF SMALL MOLECULES 
We define here small molecules as those with a molecular weight below 1 kDa. It is not by chance 
that a high percentage of currently used medical drugs fit within this definition. The main reason 
is that small molecules can be devised to penetrate into cells by simple diffusion, which requires 
that they are at least slightly soluble in the lipid bilayer.3 Therefore, such small molecules can cross 
biological barriers, enter cells, and even access cell organelles.10   
One of the best methods to predict the membrane permeability of a molecule is given by Lipinski’s 
“Rule-of-five”.11 This rule-of-five is an empirical set of parameters that allow us to predict which 
compounds are likely to be orally available drugs. However, because bioavailability and 
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membrane permeability are closely interrelated parameters, the same rule can be used to predict 
the tendency of molecules to cross the cell membrane by simple diffusion. This rule postulates that 
poor absorption or permeation is more likely to occur when: i) the molecular weight is above 500 
Dalton, ii) the molecule contains more than five hydrogen bond donors, iii) the molecule has more 
than 10 hydrogen bond acceptors, and iv) the calculated lipophilicity is more than 5.  
Another important factor, which is ignored by Lipinski’s rule, is the charge of the molecule. 
Although charged molecules are quite polar, there are several cases in which molecules with one 
or two positive charges can diffuse through the cell membrane.12,13 However, negatively charged 
molecules usually do not internalize cells efficiently. This effect stems from the fact that the 
interior of the cell is negatively charged, relative to the extracellular side and, consequently, 
molecules carrying negative charge would have to move against an electric potential gradient.14 
It is challenging to quantify the cellular uptake of small molecules, with the exception of 
fluorescent molecules, because the attachment of chemical labels can radically change their 
biological behavior. Therefore, complex approaches such as radio-labeled molecules or in vitro 
models with synthetic membranes must be used to accomplish the quantification.15  
 
Improving the cell uptake of small molecules 
Prodrug strategy: Lipophilicity is one the main parameters that determine cell uptake by simple 
diffusion. The lipophilic character of a molecule can be enhanced by means of chemical 
modifications; the simplest way involves masking polar groups such as carboxylic acids, 
phosphates, and other charged groups, by forming esters. This strategy is only useful if, after cell 
internalization, the active molecule can be regenerated by the action of cellular enzymes. Based 
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on this idea, the approach known as prodrug strategy has been developed, which consists of 
designing an inactive compound containing the parental drug, which undergoes some 
biotransformation in vivo through chemical or enzymatic cleavage, thereby enabling delivery of 
the active drug.16 This strategy can be used to improve not only cellular uptake, but also selectivity, 
and bioavailability. At present, approximately 10% of all drugs used in therapy are administered 
as prodrugs, and about half of these are hydrolyzed into the active form.17 One example is 
cidofovir, a broad-spectrum anti-DNA virus agent, active against herpesviruses. This is a highly 
polar molecule, which is therefore only slowly taken up by cells through pinocytosis. However, 
octadecyloxypropyl cidofovir, an alkoxyalkyl ester of cidofovir, can cross the cell membrane by 
simple diffusion, and the ester gets hydrolyzed by carboxylesterases after internalization. This 
hydrophobic drug analog exhibits a 4-log increase in antiviral activity against herpesvirus over 
cidofovir (Figure 2).18 
 
Figure 2.  Enzymatic hydrolysis of the prodrug octadecyloxypropyl cidofovir, which gives rise to 
the drug cidovir inside the cell. 
Cell penetrating peptides (CPPs): These are usually short, positively charged peptides (generally 
less than 30 residues) that can translocate across cell membranes at low micromolar concentration 
without harming the cellular integrity. The first known CPP was discovered from a viral protein 
possessing a peptidic segment that enables the entire protein to penetrate the cellular membrane.19 
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After this finding, an entire research field emerged, which has led to the discovery of a large variety 
of natural, synthetic, and non-peptidic CPPs. In fact, more than 800 different CPPs have been 
reported so far.20 Although the uptake mechanism of CPPs is complex, they are believed to adsorb 
onto the negatively charged cell membrane due to electrostatic interactions, which induce their 
uptake by several endocytic pathways: caveolae-mediated, clathrin-mediated, and 
macropinocytosis, followed by endosomal escape.21 CPPs can be covalently bound to small 
molecules to improve their cellular uptake, and even to allow them crossing biological barriers 
such as the blood-brain-barrier. Using small drugs such as benzylpenicillin and doxorubicin, it has 
been proven that the amount of drug transported into the brain can be enhanced up to 20-fold when 
the drug is covalently attached to a CPP.22  It should be noted that both entities should be linked 
such that the drug activity is not affected, which is probably the main limitation of combining 
CPPs with small molecules.  
A new class of promising CPPs are activatable cell penetrating peptides (ACPPs). They consist 
of a polycationic CPP bound to an inhibitory polyanion, and connected through a cleavable 
linker.23 The polyanion neutralizes the polycation and largely inhibits the CPP’s cell adhesiveness. 
Upon cleavage of the linker, the CPP is released and internalized into nearby cells. Through 
appropriate linker design, ACPPs have been directed toward extracellular enzymes, thereby 
concentrating the cargo of interest at the site of activation, where the enzyme is present. On the 
other hand, ACPPs can also be designed to respond to external stimuli, and in this way the 
spatio/temporal control of the cell uptake of molecules can be achieved.24 For instance, a new kind 
of ACPPs has been recently described, whose uptake can be induced by a host-guest complex, 
involving an anion recognition process (Figure 3).25 This approach relies on the encapsulation of 
a negatively charged pyranine that quenches the cellular uptake of a CPP.  Using an oligocationic 
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covalent cage,26 the negatively charged pyranine can be transformed into a positively charged host-
guest complex so that the quenching effect is relieved, and the ACPP activated. Interestingly, none 
of the components, the cage or the pyranine-peptide guest, are able to cross the cell membrane as 
separate units, but their association promotes the efficient uptake of both components 
simultaneously. 
 
Figure 3. a) An activable cell penetrating peptide based on a CPP (Arg8) electrostatically masked 
by a polyanionic pyranine-Glu6 domain that can be activated by the formation of a supramolecular 
host−guest complex between pyranine and the positively charged cage. b) Fluorescence 
micrographs of Vero cells after incubating the ACPP bound to a rhodamine dye, in the absence 
(top) or the presence (bottom) of 1 equiv of cage. Reproduced with permission from ref. 25. 
Copyright 2017 ACS. 
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CELLULAR UPTAKE OF BIOLOGICAL MACROMOLECULES 
Proteins and nucleic acids are promising therapeutic agents for the treatment of various diseases.27 
In most cases, cell internalization of these large molecules are indispensable for them to 
accomplish their biological functions. Unfortunately, the cellular uptake of proteins and nucleic 
acids is very inefficient for different reasons. First of all, due to their size (>1 KDa), 
macromolecules are unable to cross the cell membrane by simple diffusion. Second, endocytic 
pathways have low efficiency in the concentration ranges that these polymers are typically used, 
with the exception of those that interact with a specific receptor. Third, after endocytosis 
macromolecules remain trapped in endosomes, from where they are delivered to lysosomes to be 
hydrolyzed.28 Therefore, in contrast to small molecules for which a simple rule can predict 
internalization by simple diffusion and direct access to the cell cytoplasm; macromolecules are in 
general poorly taken up by cells, and end up being hydrolyzed inside lysosomes. Interestingly, 
covalent attachment of fluorescent dyes to these large molecules does not significantly influence 
their cell internalization, thus allowing straightforward quantification of the uptake.     
Approaches to improve cell uptake of biological macromolecules 
Cell penetrating peptides: As in the case of small molecules, CPPs can also be used to deliver 
macromolecules into the cellular cytoplasm.29 However, there are some difficulties associated to 
the larger size, as it has been reported that cargos like proteins and DNA can alter the 
internalization mechanism and endosomal escape efficiency of CPPs.30A clear example of this 
different behavior is the case of a nonpeptidic CPP based on guanidinium units. When this CPP is 
bound to small molecules such as fluorescent dyes, it specifically accumulates in mitochondria,31 
 13 
but when the same CPP is attached to a peptidic fragment of the GCN4 protein (24 amino acids), the 
resulting conjugate is completely trapped in endocytic vesicles.32  
Despite the difficulty of using CPPs with large molecules, an important advantage is related to the 
larger size. CPPs are usually positively charged molecules, in some cases also hydrophobic. When 
the cargo is negatively charged or hydrophobic, it is possible to achieve non-covalent 
complexation with CPPs, due to a large number of cooperative interactions between both 
molecules.33 The main advantage of this strategy lies in the fact that the intermolecular interactions 
are reversible, so the biological activity of the cargo is not compromised by covalent connection 
with the CPP. This non-covalent strategy has been extensively used for the cellular delivery of 
nucleic acids.34   
As mentioned above, one of the main problems of using CPPs is that most cargos remain 
entrapped in endosomes, and cannot reach their cytosolic targets. The most widely applied 
strategies to reduce endosome trapping is the use of endosomolytic peptides and membrane-
disruptive polymers, bound to CPPs.30 Endosomolytic peptides are able to break endosome 
membranes, but have a low tendency to damage the cell membrane because the lysis activity is 
triggered by endosome acidification. On the other hand, membrane-disruptive polymers can also 
rupture the endosome upon acidification, due to a proton sponge effect.35  
Interestingly, a new class of short peptide has been recently reported, which acts simultaneously 
as CPP and endosomolytic peptide.36 This peptide derives from the membrane-lytic spider venom 
peptide M-lycotoxin, in which one amino acid from the hydrophobic part of the natural peptide 
was replaced by a negatively charged glutamate. The mutated peptide is still able to adsorb onto 
the cell membrane due to its highly positive charge, thus it is quickly endocytosed, but its lytic 
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activity is dramatically reduced. Upon endosome acidification, the glutamate amino acid is 
protonated and the membrane-lytic activity recovered, thereby releasing the endosome contents 
into the cytosol (Figure 4). This CPP has three important advantages: i) it stimulates physiological 
uptake of the cargo via the induction of macropinocytosis, ii) it is compatible with non-covalent 
approaches, and iii) it is able to break endosomes and release their cargo into the cytosol. 
 
Figure 4. a) Schematic illustration of the cellular internalization mechanism for a short peptide 
derived from M-lycotoxin, which is able to release macromolecules such as antibodies into the 
cytosol. Upon endosome acidification the peptide recovers its lytic activity and releases an 
antibody from the endosome. b) Fluorescence microscopy images of HeLa cells incubated with 
Alexa488–dextran (10 kDa), in the absence and in the presence of the endosomolytic peptide. 
Scale bars: 100 µm. Reproduced with permission from ref. 36. Copyright 2017 Springer Nature.. 
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Strain-promoted thiol: Reactive disulfides can enter cells by covalent attachment through a 
disulfide exchange with cellular external thiols.37 This is the case of highly strained cyclic 
disulfides, which react mainly with the transferrin receptor (TFRC). Once cyclic disulfides are 
covalently bound to the receptor, they are transported across the cellular membrane (Figure 5). 
Importantly, the uptake efficiency of these analogs increases with the disulfide ring tension. This 
strategy has been successfully applied to the cytosolic delivery of both small and large molecules.38  
 
Figure 5. a) Schematic representation of the strain-promoted thiol uptake, applied to cell 
internalization of peptides. Solvent-exposed cysteines on the surface of TFRC react with the 
strained disulfide ring, and then the peptide is taken up by the cell. b) Fluorescence microscopy 
images of HeLa cells incubated with a peptide, without (control) and with a strained cyclic 
disulfide. Scale bars, 30 µm. Reproduced with permission from ref. 37. Copyright 2017 ACS. 
Synthetic polymers: Polymers have been largely used to achieve cellular uptake of nucleic acids, 
which are essential components of gene therapy.39 Positively charged polymers form 
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supramolecular assemblies with DNA and RNA, through electrostatic interaction, to generate polyion 
pairs. These polyions bind  onto  the  cell  surface  by  non-specific,  electrostatic interactions  between  
the  positively  charged  complexes  and  the negatively charged cell surface, entering cells via endocytic 
mechanisms. Once inside the cell, the endosomal pH drops from 7 to 5.5 and the endosome is disrupted 
by the proton sponge effect. Some examples of these polymers are polyethylenimine and 
polyamidoamine dendrimers (PAMAM).40  
CELLULAR UPTAKE OF NANOPARTICLES 
Nanoparticles (NPs) are exogenous synthetic structures with nanoscale dimensions, which have raised 
enormous interest toward biological applications. Owing to their comparatively large size, the 
cellular uptake of NPs is necessarily different to that of molecules. For example, while most 
molecules are unable to internalize cells efficiently on their own (vide supra), NPs are actively 
incorporated into the cell via different endocytic pathways.41 Additionally, owing to their efficient 
uptake, engineered NPs have been proposed to improve the cellular permeability of small molecules 
and proteins.42 The reason behind this uptake capability is that NPs feature a large and highly 
energetic surface, which is available to interact with biomolecules, such as those forming the cell 
membrane. An extensive network of cooperative weak interactions result in a high affinity between 
NPs and cells. However, this effect also has some drawbacks; when NPs are dispersed in biological 
fluids, diverse types of biomolecules (mainly proteins) readily adsorb onto the NPs forming the 
so-called protein corona (PC), which may dramatically change their biological identity, thereby 
affecting the uptake process and potentially blocking their targeting capabilities.43 
Approaches to improve cell uptake of NPs 
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Modulation of NP physicochemical properties: Although endocytic uptake is the norm for a broad 
range of NPs, various structural features should be considered, including size, shape and surface 
chemistry.41 Although there is no consensus regarding an optimum size that maximizes the level 
of cellular uptake, it seems clear that e.g. 50 nm Au NPs are taken up by cancer cells (HeLa) in 
larger amounts than both smaller and larger Au NPs, which require specific functionalization to 
achieve a similarly efficient delivery into cells.44 Surface charge is another property that plays a 
major role in the interaction with cells, so that positively charged NPs are often more efficiently 
internalized than negatively charged and neutral NPs of similar dimensions (Figure 6).45  
 
 
Figure 6. a) General structure of 2 nm Au NPs, with either cationic, anionic or zwitterionic 
headgroups. b) Cellular uptake of as-synthesized gold nanoparticles with different sizes and 
surface charge, by HeLa cells after 3 h incubation in serum-free media. Reproduced with 
permission from ref. 46. Copyright 2015 ACS. 
An important challenge in this field comprises the development of strategies toward regulating 
cell internalization by means of chemical or physical stimuli. On the basis of the surface charge 
effect, two approaches have been described to control the cellular uptake of small Au NPs (2 nm). 
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The first one involves coating the NPs with organic ligands that are neutral at pH 7.4, but become 
positively charged at acidic pH (< 6.5), thus increasing the cellular uptake in acidic environments, 
which are typical of tumor tissues.46 The second is a supramolecular approach based on the same 
host-guest strategy described in Figure 3 above, where NPs decorated with pyranines are unable 
to cross cell membranes owing to their high negative surface potential. However, they are 
efficiently internalized upon addition of the oligocationic cage, which interacts with pyranine, 
forming a positively charged host-guest complex and thereby reversing the overall surface charge. 
In contrast with the pH-responsive strategy, it has been proven that the latter method can be used 
to reversibly turn on/off NP internalization,47 thereby allowing a precise spatio/temporal control.  
Active targeting systems: A number of active delivery strategies have been tested, through 
attachment of high affinity ligands onto the surface of NPs. Internalization can then occur via 
receptor-mediated endocytosis. A broad type of ligands conjugated to metallic NPs have been used 
for such purposes, such as small molecules, carbohydrates, aptamers, or proteins.48 It is important 
to optimize the density of targeting ligands per NP to achieve high degrees of targeting efficiency 
and internalization. For instance, Au NPs with varying densities of cetuximab antibodies, which 
are active against the epidermal growth factor receptor, exhibit different uptake mechanisms.49 
Interestingly, the use of actively targeted NPs can enhance drug retention, minimize nonspecific 
uptake, and circumvent drug degradation mechanisms. 
Protein corona modulation: Adsorbed proteins confer a different biological identity to NPs, which 
may completely alter the subsequent cellular responses.50 Biomolecules can be bound through 
irreversible interactions, forming the so-called hard corona, or through weak interactions, yielding 
a soft corona. The NPs-protein complex is a complicated and dynamic entity, and its composition 
may change with time and environmental alterations, through continuous protein association and 
 19 
dissociation.51 PC usually reduces the direct contact of NPs with cell membrane components, 
producing an inhibition of the cellular uptake of NPs. However, this effect also depends on NP 
size, protein corona composition and cell type.   
The PC composition strongly influences NP interactions with cells. For example Apolipoprotein 
A mediates Au NP cell association, which has been used for brain targeting strategies, whereas the 
presence of Immunoglobulin G in the PC can inhibit this effect.52 PC formation may reduce or 
even block the targeting capabilities of NPs, by inhibiting the binding with their target site. Coating 
of NPs with polyethylene glycol (PEG) has proven useful to partly inhibit PC formation, and this 
effect has been used e.g. to restore the targeting ability of Hercepcin-targeted AuNPs.53 An 
alternative protective coating is provided by low-molecular-weight glycans, which have been used 
to stabilize Au NPs of different shapes in biofluids. Glycan-coated NPs were resistant to adsorption 
of proteins from serum-containing media and to prevent phagocytosis by macrophage-like cells, 
but retained carbohydrate-binding targeting capabilities toward tumor cells (Figure 7).54  
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Figure 7. Biological behavior of gold nanorods stabilized with long PEG ligands and with a short 
organic ligand containing lactose (Lac). a) Organic structure of the ligands. b) Fluorescence 
microscopy images of DLD1 cancer cells incubated with fluorescently labeled AuNRs-Lac (upper 
panel) and AuNRs-PEG (lower panel). (1) Brightfield and DAPI fluorescence overlay. (2) 
Fluorescence signal from AuNRs. c) Comparison of the degree of protein immobilization on 
AuNRs coated with different ligands, upon exposure to 10% fetal bovine serum in phosphate-
buffered saline. CTAB is hexadecyltrimethylammonium bromide. Reproduced with permission 
from ref. 54. Copyright 2015 ACS. 
Endosomal escape: Many biomedical applications will ultimately require intracellular delivery, as 
well as availability of the NP, not only to a certain type of cells, but also to specific subcellular 
compartments. Although emphasis is often placed on the importance of regulating NPs uptake, 
endosomal escape is perhaps the most challenging barrier against the delivery of NPs. Although 
several approaches have been explored to achieve the release of NPs from endosomes, no strategy 
has been proven efficient so far, without damaging the cells. We highlight here three strategies; 
binding of polymers that can disrupt the endosome by the proton sponge effect,55 nanocapsules that 
can internalize the cell through membrane fusion for internalization of 2 nm NPs,56 and laser 
irradiation of plasmonic Au NPs.57 
  
CONCLUSIONS AND OUTLOOK  
We have shown that size is an important parameter that must be considered when aiming at an 
efficient cellular uptake for a synthetic structure. Each range of sizes has their own advantages and 
disadvantages. In summary, small and lipophilic molecules can cross the cell membrane by simple 
diffusion and access all cell compartments, whereas internalization of small polar molecules and 
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macromolecules is challenging. On the other hand, NPs are easily taken up by cells, but they 
usually remain trapped in endosomes. Although we present in this Account several strategies that 
can be used to improve the cell internalization properties for each size range, there is still a long 
way to go before cellular uptake is mastered. Particularly challenging is avoiding endosomal 
entrapment of NPs and macromolecules. Although several strategies have been developed to solve 
this problem, only a small part of the internalized chemical structures are usually able to escape 
lysosomal degradation, using currently existing methods.  
In contrast, medicine is currently entering the age of precision and personalized treatments; it 
seems thus likely that future medicine will be mainly based on the use of proteins and nucleic acids 
as future drugs, while NPs may act as drug delivery platforms that are selective toward a specific 
kind of cells. Therefore, there is a great need for strategies that can bypass lysosomes, so that large 
drug carriers can reach the inner side of cells. A possible solution is the development of chemical 
vectors that induce selectively cell internalization by caveolin-mediated endocytosis, which is used 
by some viruses and bacteria, to avoid lysosomal degradation.58  
On the other hand, an ideal drug delivery platform must be able to internalize only the target cells, 
and to subsequently release the drug avoiding side effects. In order to achieve this goal, efficient 
ways to reduce or modulate PC formation on NPs must be identified. The performance of the 
current methods, mainly based on PEG ligands as coating agents, are far from ideal. As a 
consequence, the physico-chemical properties of NPs change in the presence of biological media, 
thereby hindering their targeting capabilities. 
Finally, it is also worth noting that a major challenge in this area comprises the development of 
approaches to achieve spatio/temporal control of cellular internalization using external stimuli. We 
discussed above several ways to activate cellular uptake based on chemical stimuli, but such 
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strategies are difficult to apply in living organisms. Additional research should be carried out to 
achieve the same performance but applying physical stimuli such as near infrared light, magnetic 
fields or ultrasound, which are harmless to biological tissues. 
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